AN2 Therapeutics, Inc. (ANTX) vs RxSight, Inc. (RXST)

A side-by-side comparison of AN2 Therapeutics, Inc. and RxSight, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANTX

AN2 Therapeutics, Inc.

$183M

$5.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RXST

RxSight, Inc.

$192M

$4.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANTX vs RXST

growth of $100 · dividends reinvested · last 5y

ANTX -63.6% (-18.3%/yr)RXST -60.8% (-17.1%/yr)RXST compounded faster over this window

ANTX RXST

ANTX vs RXST: by the numbers

•RXST is the larger company ($192M vs $183M market cap).
•Both run net losses; ANTX's is the smaller (0.00% vs -36.80% net margin).

Metrics side by side

Valuation

Metric	ANTX	RXST
P/S ratio	N/A	1.51
P/B ratio	2.41	0.73

Profitability

Metric	ANTX	RXST
Gross margin	0.00%	77.50%
Operating margin	0.00%	-43.20%
Net margin	0.00%	-36.80%
ROE	-47.78%	-17.83%
ROIC	-51.01%	-20.24%

Growth (annualized)

Metric	ANTX	RXST
Revenue CAGR (5Y)	N/A	48.85%
Total return CAGR (5Y)	N/A	-19.19%

Go deeper

Full ANTX analysis Full RXST analysis Interactive comparison tool

Dig into the metrics

AN2 Therapeutics ROE RxSight ROE AN2 Therapeutics operating margin RxSight operating margin AN2 Therapeutics revenue growth RxSight revenue growth AN2 Therapeutics free cash flow RxSight free cash flow

AN2 Therapeutics & RxSight appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.